MUSCARINIC ACETYLCHOLINE RECEPTOR M3

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Approval Year

Substance Class	Protein Created by `admin` on `Sun Dec 18 08:11:55 UTC 2022` Edited by `admin` on `Sun Dec 18 08:11:55 UTC 2022`
Protein Sub Type
Sequence Origin	HUMAN
Sequence Type	COMPLETE
Record UNII	W3JX5KZ4V2
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MUSCARINIC ACETYLCHOLINE RECEPTOR M3

Common Name

English

CHRM3

Common Name

English

Code System Code Type Description

FDA UNII

W3JX5KZ4V2

Created by admin on Sun Dec 18 08:11:58 UTC 2022 , Edited by admin on Sun Dec 18 08:11:58 UTC 2022

PRIMARY

UNIPROT

P20309

Created by admin on Sun Dec 18 08:11:58 UTC 2022 , Edited by admin on Sun Dec 18 08:11:58 UTC 2022

PRIMARY

PHAROS

P20309

Created by admin on Sun Dec 18 08:11:58 UTC 2022 , Edited by admin on Sun Dec 18 08:11:58 UTC 2022

PRIMARY

From	To
1_141	1_221
1_517	1_520

Glycosylation Type

HUMAN

Glycosylation Link Type	Site
N	1_5
N	1_6
N	1_15
N	1_41
N	1_48

Related Record Type Details


					5BRQ29UUB7

INHIBITOR -> TARGET

Amount:


					AC72FH2XG6

CHF-6366 muscarinic metabolite

NON-INHIBITOR->OFF TARGET

Comments:

Corresponding M3 fragment acid 19 elicited no significant M3 effect when dosed at 1 nmol/kg, strongly supporting our rationale of combining the two pharmacologies into a single agent through a labile moiety.

Qualification:

Ki

Amount:


					G2AE2VE07O

INHIBITOR -> TARGET

Comments:

In the airways, it exhibits pharmacological effects through inhibition of M3 receptor at the smooth muscle leading to bronchodilation.

Interaction Type:

BINDING

Qualification:

Kd

Amount:


					K17VY42F6C

ANTAGONIST->TARGET

Qualification:

Ki

Amount:


					HFU99SBD7V

INHIBITOR -> TARGET

Comments:

Binding assay

Qualification:

IC50

Amount:


					838F01T721

NON-INHIBITOR->OFF TARGET

Interaction Type:

NON-INHIBITOR

Qualification:

Ki

Amount:


					05VP796JC6

MEQUITAZINE, (R)-

INHIBITOR -> TARGET

Comments:

S-ISOMER BINDS WITH LESS AVIDITY

Qualification:

IC50

Amount:


					V92SO9WP2I

INHIBITOR -> TARGET

Qualification:

Ki

Amount:


					GE2T1418SV

INHIBITOR -> TARGET


					00Y6A5AJU6

INHIBITOR -> TARGET

Amount:


					U29GY32XJ4

INHIBITOR -> TARGET


					7C0697DR9I

ATROPINE

INHIBITOR -> TARGET

Amount:


					6ZE7T2VQ9F

CHF-6366

INHIBITOR -> TARGET

Qualification:

Ki

Amount:


					5ASJ6HUZ7D

DOXEPIN

INHIBITOR -> TARGET


					YU871O78GR

DESFESOTERODINE

INHIBITOR -> TARGET


					A6X64T4LZ4

INHIBITOR -> TARGET

Comments:

THRX-195518 possesses activity at target muscarinic receptors that was slightly lower (approximately one-third to one-tenth) than revefenacin.

Interaction Type:

BINDING

Qualification:

Ki

Amount:


					JJH94R3PWB

NERATINIB

INHIBITOR->OFF-TARGET

Comments:

Radioligand binding assay

Interaction Type:

BINDING

Qualification:

IC50

Amount:


					L6UH7ZF8HC

NON-INHIBITOR->OFF TARGET

Amount:


					WHE7A56U7K

INHIBITOR -> TARGET


					O0RG3QM34H

INHIBITOR -> TARGET

Amount:


					K9P6MC7092

INHIBITOR -> TARGET


					A8910SQJ1U

INHIBITOR -> TARGET

Comments:

Appears to be more bladder-selective for the M3 receptor relative to salivary glands.eptor

Qualification:

Ki

Amount:


					01MI4Q9DI3

AGONIST -> TARGET

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
MOL_WEIGHT	CHEMICAL